Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Etripamil Nasal Spray for Ventricular Rate Reduction in Atrial Fibrillation
2022-001854-49Phase 2Completed
- Sponsor
- Milestone Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Etripamil nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Ventricular rate reduction. Started Aug 2022; status: completed.
02
Drugs
etripamil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2022-001854-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001854-49.